VIDEO: Capivasertib may ‘represent a new treatment strategy’ in advanced breast cancer
In this video, Sara M. Tolaney, MD, MPH, discusses recent findings examining the use of capivasertib and fulvestrant in patients with aromatase inhibitor-resistant hormone receptor-positive, HER2-negative advanced breast cancer.
The results from the CAPItello-291 trial were presented at this year’s San Antonio Breast Cancer Symposium.
“This was looked at in an all-comer population, irrespective of biomarker as an initial analysis, where it did show that capivasertib [AZD5363, AstraZeneca] did improve PFS in the [intention-to-treat] population, but also when specifically looking at biomarker-altered patients, so those patients with PI3K mutation, AKT mutation, or PTEN alteration, which was almost 40% of patients in this study,” Tolaney, chief of the division of breast oncology at Susan F. Smith Center for Women's Cancers in the Dana Farber Cancer Institute, said. “You see that that group also derived benefit from capivasertib with a benefit that was slightly larger, so the hazard ratio for the PIK3 altered group was around 0.5 [adjusted HR = 0.5; 95% CI, 0.38-0.65], compared [with] about 0.6 [HR = 0.6; 95% CI, 0.51-0.71] in the ITT population.”
She added that while the nonaltered group had a hazard ratio of 0.7 (95% CI, 0.56-0.88) some patients included in the group had unknown biomarker status, so additional research is needed to determine the full benefit in unaltered patients.
“I think this could represent a new treatment strategy for our patients, particularly post CDK4/6 inhibition, so I think we’re really all excited to see that potentially this agent could get approved,” she said, adding that it “would be wonderful, particularly for the altered patients, and for potentially some nonaltered patients, as we get more data.”
Collapse